A drug called sorafenib stopped progression of desmoid tumors for 80 percent of patients taking the drug over a two-year period as part of a phase 3 trial.
from Latest Science News -- ScienceDaily https://ift.tt/2LteupE
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment